Share on LinkedInShare on LinkedIn

ARTICLE · 27 APRIL 2026

Prescription Change: DOJ Reclassifies State-Licensed And FDA-Approved Marijuana Products

Cassels
Cassels
Contributor
Cassels

Cassels

Cassels Brock & Blackwell LLP is a Canadian law firm focused on serving the transaction, advocacy,...

View firm profile
Explore more from Cassels

The DOJ also announced a new expedited administrative hearing process to consider the broader rescheduling of marijuana from Schedule I to Schedule III.

CanadaCannabis & Hemp

On April 23, 2026, the U.S. Department of Justice (the DOJ) announced the issuance of a final order (the Order) immediately placing two categories of marijuana from Schedule I to Schedule III under the Controlled Substances Act (the CSA): (i) drug products containing marijuana that have been approved by the U.S. Food and Drug Administration (the FDA), and (ii) marijuana products subject to a qualifying state-issued medical marijuana license. The DOJ also announced a new expedited administrative hearing process to consider the broader rescheduling of marijuana from Schedule I to Schedule III.

The Order follows President Trump’s Executive Order on Increasing Medical Marijuana and Cannabidiol Research, issued on December 18, 2025, which directed the Attorney General to complete the rulemaking process related to rescheduling marijuana to Schedule III “in the most expeditious manner” in accordance with U.S. federal law. Further details of the executive order can be

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from